Literature DB >> 16879631

Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice.

L Pennanen1, D P Wolfer, R M Nitsch, J Götz.   

Abstract

The neuropathological hallmark shared between Alzheimer's disease (AD) and familial frontotemporal dementia (FTDP-17) are neurofibrillary tangles (NFT) which are composed of filamentous aggregates of the microtubule-associated protein tau. Their formation has been reproduced in transgenic mice, which express the FTDP-17-associated mutation P301L of tau. In these mice, tau aggregates are found in many brain areas including the hippocampus and the amygdala, both of which are characterized by NFT formation in AD. Previous studies using an amygdala-specific test battery revealed an increase in exploratory behavior and an accelerated extinction of conditioned taste aversion in these mice. Here, we assessed P301L mice in behavioral tests known to depend on an intact hippocampus. Morris water maze and Y-maze revealed intact spatial working memory but impairment in spatial reference memory at 6 and 11 months of age. In addition, a modest disinhibition of exploratory behavior at 6 months of age was confirmed in the open field and the elevated O-maze and was more pronounced during aging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879631     DOI: 10.1111/j.1601-183X.2005.00165.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  30 in total

1.  Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.

Authors:  Julio J Ramirez; Winona E Poulton; Erik Knelson; Cole Barton; Michael A King; Ronald L Klein
Journal:  Behav Brain Res       Date:  2010-08-19       Impact factor: 3.332

Review 2.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

3.  Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice.

Authors:  Samra Nazir; Fareeha Anwar; Uzma Saleem; Bashir Ahmad; Zohaib Raza; Maham Sanawar; Artta Ur Rehman; Tariq Ismail
Journal:  Neurochem Res       Date:  2021-04-20       Impact factor: 3.996

4.  Transgenic mice with increased astrocyte expression of CCL2 show altered behavioral effects of alcohol.

Authors:  Jennifer G Bray; Amanda J Roberts; Donna L Gruol
Journal:  Neuroscience       Date:  2017-04-19       Impact factor: 3.590

Review 5.  Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.

Authors:  Anne Eckert; Kathrin L Schulz; Virginie Rhein; Jürgen Götz
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

6.  Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice.

Authors:  Dave Morgan; Sanjay Munireddy; Jennifer Alamed; Jason DeLeon; David M Diamond; Paula Bickford; Michael Hutton; Jada Lewis; Eileen McGowan; Marcia N Gordon
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

7.  Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice.

Authors:  Anne Eckert; Susanne Hauptmann; Isabel Scherping; Jessica Meinhardt; Virginie Rhein; Stefan Dröse; Ulrich Brandt; Marcus Fändrich; Walter E Müller; Jürgen Götz
Journal:  J Mol Med (Berl)       Date:  2008-08-16       Impact factor: 4.599

8.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

9.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

10.  Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Yazi D Ke; Fabien Delerue; Amadeus Gladbach; Jürgen Götz; Lars M Ittner
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.